Status:
UNKNOWN
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Amphetamine-Related Disorders
Eligibility:
All Genders
21-45 years
Phase:
PHASE1
Brief Summary
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and...
Detailed Description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and...
Eligibility Criteria
Inclusion
- Please contact site for more details
Exclusion
- Please contact site for more details
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00267657
Start Date
January 1 2004
End Date
November 1 2004
Last Update
January 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U of CA, San Francisco
San Francisco, California, United States, 94143